Kite, a Gilead Company, to present cell therapy research at the virtual 46th Annual Meeting of the European Society for Blood and Marrow Transplantation
- Kite, a Gilead Company, is pleased to present data at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), taking place virtually from 29 August-01 September 2020.
- The meeting will bring together thousands of experts from across Europe to address the needs of patients with blood cancers and other life-threatening diseases, by advancing the fields of blood and marrow transplantation and cell therapy through science, education and patient care.
- Kite will be presenting data from its cell therapy research programmes to attending healthcare professionals.
“The Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) has always been an important knowledge-sharing platform for those at the cutting edge of cancer treatment,” said Dick Sundh, Vice President, Head of Australia, Canada and Europe, Kite. “To address ongoing patient needs in difficult-to-treat blood cancers, it is important to continue to understand developments in treatments and technologies through ongoing clinical research, and we are pleased to share our findings during the meeting.”
Presentations at the meeting will include:
|
Presentation Number and Presenter |
Abstract Title |
|
Abstract #0036 (ePoster with audio)* Presenter: Michael L Wang, The University of Texas MD Anderson Cancer Center, Houston |
KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL): results from Phase 2 of ZUMA-2 – Michael L Wang, The University of Texas MD Anderson Cancer Center, Houston |
|
Abstract #0045 (ePoster with audio)* Presenter: Sattva S Neelapu, The University of Texas MD Anderson Cancer Center, Houston |
A comparison of two-year outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in patients with refractory large B cell lymphoma – Sattva S Neelapu, The University of Texas MD Anderson Cancer Center, Houston |
|
Abstract #A081 (ePoster)* Presenter: Anne Kerber, Vice President, Head of Clinical Development EU, Kite |
Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B cell lymphoma – Max S Topp, Head of Haematology at University Hospital of Würzburg |
* ePosters will be available on Saturday, 29 August 12:30pm-18:30pm CET; Sunday, 30 August 08:30am-19:00pm CET; Monday, 31 August 09:30am-19:00pm CET; Tuesday, 01 September 09:30am-18:00pm CET.
The following experts will be available for comment on Kite activities throughout the virtual meeting:
- Dick Sundh, Vice President, Head of Australia, Canada and Europe, Kite
- Anne Kerber, Vice President, Head Clinical Development EU, Kite
- Louis van de Wiel, Vice President, Site Head Kite Europe
For more information or to arrange a reactive interview please contact Cressida Robson, Media (Australia, Canada and Europe), Kite (+44 7341 789 204 or cressida.robson@kitepharma.com).
# # #
KTE-X19 is investigational and not approved in Europe. Its efficacy and safety have not been established. More information about clinical trials with KTE-X19 is available at www.clinicaltrials.gov.
In August 2018, axicabtagene ciloleucel, a CAR T cell therapy, received European Marketing Authorisation for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.[i]
[i] European Medicines Agency. Yescarta® (axicabtagene ciloleucel) SPC. Available at: https://www.ema.europa.eu/documents/product-information/yescarta-epar-product-information_en.pdf. Accessed August 2020.
Editor Details
-
Company:
- Kite, a Gilead Company
-
Name:
- Kite, a Gilead Company
